Conclusions: Resveratrol and its analogues can mimic caloric restriction with complex mechanisms, including activation of SIRT1, PGC-1α, and JNK, making them possible drug candidates to treat obesity-related diseases. The gene discussed is PPARGC1A; the disease is obesity due to melanocortin 4 receptor deficiency.